The company has received tentative approval from the US Food and Drug AdministrationUSFDA to market Osimertinib tablets in the strengths of 40 mg and 80 mg, Zydus Cadila, part of the Cadila Healthcare group, said in a regulatory filing.
Osimertinib is used to treat lung cancer. Osimertinib works by slowing or stopping the growth of cancer cells.
The company said the newly approved medication will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 318 approvals and has so far filed over 400 abbreviated new drug applications since the commencement of the filing process in the financial year 2003-04.
Zydus Cadila gets tentative USFDA nod to market lung cancer treatment drug
Drug firm Zydus Cadila on Thursday said it has received tentative approval from the US health regulator to market Osimertinib tablets, used to treat lung cancer.
The company has received tentative approval from the US Food and Drug Administration USFDA to market Osimertinib tablets in the strengths of 40 mg and 80 mg, Zydus Cadila, part of the Cadila Healthcare group, said in a regulatory filing.
Osimertinib is used to treat lung cancer. Osimertinib works by slowing or stopping the growth of cancer cells.
The company said the newly approved medication will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 318 approvals and has so far filed over 400 abbreviated new drug applications since the commencement of the filing process in the financial year 2003-04.
Source:https://health.economictimes.indiatimes.com/news/pharma/zydus-cadila-gets-tentative-usfda-nod-to-market-lung-cancer-treatment-drug/83201464
Recent Posts
Recent Comments
About Me
Zulia Maron Duo
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore.
Popular Categories
Archives
Meta
Archives
Categories
Meta
Popular Post
BDR Pharma launches the first generic RUCAPARIB
July 28, 2021Lupin receives $50 million from Boehringer Ingelheim
July 28, 2021Novartis announces positive data from phase II
July 28, 2021